Erytech Pharma SA-Product Pipeline Review-2015

Erytech Pharma SA-Product Pipeline Review-2015

  • Products Id :- GMDHC07305CDB
  • |
  • Pages: 33
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Erytech Pharma SA-Product Pipeline Review-2015


Global Markets Direct's, 'Erytech Pharma SA-Product Pipeline Review-2015', provides an overview of the Erytech Pharma SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Erytech Pharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Erytech Pharma SA including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Erytech Pharma SA's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Erytech Pharma SA's pipeline products

Reasons To Buy

Evaluate Erytech Pharma SA's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Erytech Pharma SA in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Erytech Pharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Erytech Pharma SA and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Erytech Pharma SA

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Erytech Pharma SA and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Erytech Pharma SA Snapshot 5

Erytech Pharma SA Overview 5

Key Information 5

Key Facts 5

Erytech Pharma SA-Research and Development Overview 6

Key Therapeutic Areas 6

Erytech Pharma SA-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Erytech Pharma SA-Pipeline Products Glance 10

Erytech Pharma SA-Late Stage Pipeline Products 10

Phase III Products/Combination Treatment Modalities 10

Erytech Pharma SA-Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Phase I Products/Combination Treatment Modalities 12

Erytech Pharma SA-Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Erytech Pharma SA-Drug Profiles 14

asparaginase 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

Cell therapy for Phenylketonuria 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Enhoxy 17

Product Description 17

Mechanism of Action 17

R&D Progress 17


Product Description 18

Mechanism of Action 18

R&D Progress 18


Product Description 19

Mechanism of Action 19

R&D Progress 19


Product Description 20

Mechanism of Action 20

R&D Progress 20

Erytech Pharma SA-Pipeline Analysis 21

Erytech Pharma SA-Pipeline Products by Target 21

Erytech Pharma SA-Pipeline Products by Route of Administration 22

Erytech Pharma SA-Pipeline Products by Molecule Type 23

Erytech Pharma SA-Pipeline Products by Mechanism of Action 24

Erytech Pharma SA-Recent Pipeline Updates 25

Erytech Pharma SA-Dormant Projects 30

Erytech Pharma SA-Locations And Subsidiaries 31

Head Office 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Tables

Erytech Pharma SA, Key Information 5

Erytech Pharma SA, Key Facts 5

Erytech Pharma SA-Pipeline by Indication, 2015 7

Erytech Pharma SA-Pipeline by Stage of Development, 2015 8

Erytech Pharma SA-Monotherapy Products in Pipeline, 2015 9

Erytech Pharma SA-Phase III, 2015 10

Erytech Pharma SA-Phase II, 2015 11

Erytech Pharma SA-Phase I, 2015 12

Erytech Pharma SA-Preclinical, 2015 13

Erytech Pharma SA-Pipeline by Target, 2015 21

Erytech Pharma SA-Pipeline by Route of Administration, 2015 22

Erytech Pharma SA-Pipeline by Molecule Type, 2015 23

Erytech Pharma SA-Pipeline Products by Mechanism of Action, 2015 24

Erytech Pharma SA-Recent Pipeline Updates, 2015 25

Erytech Pharma SA-Dormant Developmental Projects,2015 30

List of Figures

Erytech Pharma SA-Pipeline by Top 10 Indication, 2015 7

Erytech Pharma SA-Pipeline by Stage of Development, 2015 8

Erytech Pharma SA-Monotherapy Products in Pipeline, 2015 9

Erytech Pharma SA-Pipeline by Top 10 Target, 2015 21

Erytech Pharma SA-Pipeline by Top 10 Route of Administration, 2015 22

Erytech Pharma SA-Pipeline by Top 10 Molecule Type, 2015 23

Erytech Pharma SA-Pipeline Products by Top 10 Mechanism of Action, 2015 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Erytech Pharma SA; Erytech Pharma SA - Key Therapeutics; Erytech Pharma SA - Pipeline Overview and Promising Molecules; Erytech Pharma SA - News; Erytech Pharma SA - Latest Updates; Erytech Pharma SA - Pipeline; Erytech Pharma SA - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97065
Site License
USD 3000 INR 194130
Corporate User License
USD 4500 INR 291195



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]